PMID- 32569633
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 509
DP  - 2020 Oct
TI  - Serum CXC chemokine ligand-12 as a potential predictor for in-hospital major 
      adverse events after severe traumatic brain injury.
PG  - 244-248
LID - S0009-8981(20)30296-5 [pii]
LID - 10.1016/j.cca.2020.06.031 [doi]
AB  - BACKGROUND: CXC chemokine ligand-12 (CXCL12) is associated with brain 
      inflammation. We attempted to discern whether serum CXCL12 is a promising 
      predictor for in-hospital major adverse events (IMAEs) after traumatic brain 
      injury (TBI), including death, acute lung injury, acute traumatic coagulopathy, 
      progressive hemorrhagic injury and posttraumatic cerebral infarction. METHODS: In 
      this prospective, observational study, serum CXCL12 levels were quantified among 
      117 severe TBI patients. We investigated the relation of CXCL12 levels to IMAEs 
      using a multivariate analysis. RESULTS: Median value of serum CXCL12 
      concentrations was substantially higher in patients with IMAEs than in other 
      remainders (21.1 vs. 11.6 ng/ml). With an increasing number of IMAEs, serum 
      CXCL12 concentrations were significantly increased (r = 0.702). Serum CXCL12 
      independently predicted IMAEs (odds ratio, 1.253; 95% CI, 1.100-1.428). Serum 
      CXCL12 concentrations discriminated risk of IMAEs with area under receiver 
      operating characteristic curve of 0.759 (95% CI, 0.672-0.834), its concentrations 
      >16.0 ng/ml distinguished IMAEs with 83.9% sensitivity and 67.2% specificity and 
      its combination with Glasgow coma scale scores produced the best predictive 
      ability compared with each one alone (p = 0.0116 or 0.0004). CONCLUSION: Serum 
      CXCL12 concentrations are independently associated with IMAEs following TBI, 
      substantializing serum CXCL12 as a useful prognostic biomarker for head trauma 
      patients.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Shen, Liang-Jun
AU  - Shen LJ
AD  - Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated 
      Hospital of Zhejiang University Shengzhou branch), No. 666 Dangui Road, Shengzhou 
      312400, Zhejiang, China. Electronic address: shengzhoushenlj@163.com.
FAU - Zhou, Jing
AU  - Zhou J
AD  - Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated 
      Hospital of Zhejiang University Shengzhou branch), No. 666 Dangui Road, Shengzhou 
      312400, Zhejiang, China.
FAU - Yang, Chun-Song
AU  - Yang CS
AD  - Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated 
      Hospital of Zhejiang University Shengzhou branch), No. 666 Dangui Road, Shengzhou 
      312400, Zhejiang, China.
FAU - Lv, Qing-Wei
AU  - Lv QW
AD  - Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated 
      Hospital of Zhejiang University Shengzhou branch), No. 666 Dangui Road, Shengzhou 
      312400, Zhejiang, China.
FAU - Xu, Qi-Chen
AU  - Xu QC
AD  - Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated 
      Hospital of Zhejiang University Shengzhou branch), No. 666 Dangui Road, Shengzhou 
      312400, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200620
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Ligands)
SB  - IM
MH  - *Brain Injuries, Traumatic/diagnosis
MH  - Chemokine CXCL12
MH  - Glasgow Coma Scale
MH  - Hospitals
MH  - Humans
MH  - Ligands
MH  - Prognosis
MH  - Prospective Studies
OTO - NOTNLM
OT  - Biomarker
OT  - CXC chemokine ligand-12
OT  - Prognosis
OT  - Traumatic brain injury
EDAT- 2020/06/23 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S0009-8981(20)30296-5 [pii]
AID - 10.1016/j.cca.2020.06.031 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2020 Oct;509:244-248. doi: 10.1016/j.cca.2020.06.031. Epub 2020 
      Jun 20.